

A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Vertex Pharmaceuticals Incorporated
Enrollment	176 participants

Key Eligibility Criteria

Inclusion (1)

- Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility

Exclusion (1)

- Hypersensitivity to investigational medicinal product or to any of its excipients

Locations (73 total)

Renal Associates, Montgomery, Alabama, United States
Southwest Kidney Institute, PLC (SKI) - Surprise, Surprise, Arizona, United States
Academic Medical Research Institute (AMRI), Los Angeles, California, United States
... and 70 more locations